Adjunctive Pentoxifylline Enhances Clinical Remission and Reduces Inflammatory Biomarkers in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-Controlled Pilot Trial
Mohannad O Khrieba·Marwa Kamal·Amal Mohammed Badawoud·Eman Hamza·Reham Abdullah Al-Dhelaan·Tarek I. Ahmed·ahmed abdelhameed·Nora Elshorbagi·Doaa A El-Hanafy·Nashwa Eltantawy·Muhammed M. Salahuddin·Noha M. Elkhodary·Kholoud H. Radwan·Khaled Abo Bakr Khalaf Ali·Abeer A. El-Sayed·Furqan M. Abdulelah
Background: Despite mesalamine’s efficacy in mild-to-moderate ulcerative colitis (UC), many patients fail to achieve complete clinical or biochemical remission. Pentoxifylline (PTX) may act as an adjunct therapy by modulating cytokine production and oxidative stress. Aim: To evaluate the therapeutic effect of adding PTX in patients with UC. Methods: In this randomized, double-blind, placebo-controlled pilot study, 60 patients with UC were assigned to mesalamine plus placebo (Group 1) or mesalami